Immune checkpoint inhibitors, such as anti-PD-L1 therapies, have shown promise in patients in the ICU with COVID-19, where upregulation of PD-L1 and PD-L2 has been linked to higher mortality [43,111,112,113]. Here, PDCD1LG2 is linked to COVID-19.